Insider Selling: Kestra Medical Technologies (NASDAQ:KMTS) Insider Sells $412,200.00 in Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Brian Daniel Webster sold 15,000 shares of the firm’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $27.48, for a total value of $412,200.00. Following the sale, the insider directly owned 460,215 shares of the company’s stock, valued at approximately $12,646,708.20. This represents a 3.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Brian Daniel Webster also recently made the following trade(s):

• On Tuesday, August 4th, Brian Daniel Webster sold 51,900 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $24.52, for a total transaction of $1,272,588.00.
• On Monday, August 3rd, Brian Daniel Webster sold 13,017 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $23.92, for a total transaction of $311,366.64.
• On Friday, July 31st, Brian Daniel Webster sold 8,948 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $22.60, for a total transaction of $202,224.80.
• On Thursday, July 30th, Brian Daniel Webster sold 7,857 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $22.72, for a total transaction of $178,511.04.
• On Monday, June 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $20.81, for a total transaction of $312,150.00.

Kestra Medical Technologies Price Performance

Kestra Medical Technologies stock traded up $0.11 during trading on Tuesday, hitting $27.93. The stock had a trading volume of 249,303 shares, compared to its average volume of 324,989. The stock’s 50 day moving average is $24.13 and its two-hundred day moving average is $22.74. Kestra Medical Technologies, Ltd. has a 1 year low of $15.42 and a 1 year high of $30.00. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.41 and a quick ratio of 4.41.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.08). Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. The firm had revenue of $28.64 million during the quarter. Analysts predict that Kestra Medical Technologies, Ltd. will post -2.29 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Farther Finance Advisors LLC purchased a new stake in shares of Kestra Medical Technologies in the fourth quarter worth $31,000. Russell Investments Group Ltd. increased its stake in Kestra Medical Technologies by 43.5% in the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock worth $41,000 after acquiring an additional 474 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in shares of Kestra Medical Technologies by 148.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock valued at $65,000 after acquiring an additional 1,638 shares in the last quarter. Daiwa Securities Group Inc. purchased a new stake in shares of Kestra Medical Technologies in the 4th quarter valued at about $72,000. Finally, Brown Brothers Harriman & Co. boosted its position in shares of Kestra Medical Technologies by 26.8% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock valued at $74,000 after acquiring an additional 656 shares during the last quarter.

Analysts Set New Price Targets

A number of equities analysts have weighed in on KMTS shares. Wolfe Research set a $30.00 target price on shares of Kestra Medical Technologies in a research report on Wednesday, July 15th. BTIG Research raised their price target on Kestra Medical Technologies from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Oppenheimer started coverage on Kestra Medical Technologies in a research report on Tuesday, July 21st. They issued a “market perform” rating for the company. Weiss Ratings upgraded Kestra Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Finally, Wall Street Zen upgraded Kestra Medical Technologies from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Kestra Medical Technologies has an average rating of “Hold” and an average target price of $28.14.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.